Building Competency in Diabetes Education THE ESSENTIALS

TREATMENT MODALITIES: PHARMACOLOGICAL THERAPIES | 6-137

185. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38:2217-25. 186. White JR Jr. Advances in insulin therapy: A review of new insulin glargine 300 units/mL in the management of diabetes. Clin Diabetes 2016;34:86-91. 187. Bergenstal RM, Bailey TS, Rodbard D, et al. Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 2017;40:554-60. 188. Novo Nordisk Canada Inc. Tresiba® product monograph. Mississauga: Novo Nordisk Canada, 2018. 189. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus largine in type 2 diabetes. N Engl J Med 2017;377:723-32. 190. Lane W, Bailey TS, Gerety G, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: The SWITCH 1 randomized clinical trial. JAMA 2017;318:33-44. 191. Zhang XW, Zhang X, Xu B, et al. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: A meta-analysis of randomized controlled trials. Acta Diabetol 2018;55:429-41. 192. Bolli GB , Cheng A, Bosnyak Z, et al. Lower hypoglycemia rates with insulin glargine 300 U/mL (Gla-300) vs. insulin degludec 100 U/mL (IDeg-100) in insulin-naïve adults with T2DM on oral antihyperglycemic therapy ± GLP-1RA—The BRIGHT randomized study. Diabetes 2018;67(Suppl 1):Poster. 193. Cheng A , Rosenstock J, Ritzel R, et al. Similar glycemic control and less or comparable hypoglycemia with insulin glargine 300 U/mL (Gla-300) vs. degludec 100 U/mL (IDeg-100) in insulin-naïve T2DM on antihyperglycemic drugs ± GLP-1 RAs—The BRIGHT randomized study. Diabetes 2018;67(Suppl 1):Poster. 194. Tibaldi O, Haldrup S, Sandberg V, et al. Clinical outcome assessment of the effectiveness of insulin degludec (Degludec) in real-life medical practice (CONFIRM)—A comparative effectiveness study of degludec and insulin glargine 300U/mL (glargine U300) in insulin- naïve patients with type 2 diabetes (T2D). Diabetes 2018;67(Suppl 1):Poster. 195. Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real ‐ world patients with type 2 diabetes switching from first ‐ to second ‐ generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+

cohort study. Diabetes Obes Metab 2018;20:2148-58.